Other studies have shown that in NSCLC and urothelial carcinoma patients treated with PD‐1/PD‐L1 immunotherapy, higher TMB was significantly correlated with a higher tumor objective response rate (ORR), longer sustained clinical benefit time, and better progression‐free survival (PFS).9 This evidence concerns the gene CD274 and non-small cell lung carcinoma.